NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
Want to see NRXP full AI Analyst Report?
NRXP Stock Chart & Stats
$2.55
-$0.69(-14.70%)
At close: 4:00 PM EST
$2.55
-$0.69(-14.70%)
Day’s Range― - ―
52-Week Range$1.62 - $4.59
Previous CloseN/A
Volume2.07M
Average Volume (3M)475.66K
Market Cap
$160.86M
Enterprise Value$70.97M
Total Cash (Recent Filing)$6.71M
Total Debt (Recent Filing)$934.00K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 17, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding36,228,992
10 Day Avg. Volume509,446
30 Day Avg. Volume475,656
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-3.64
Price to Sales (P/S)47.35
P/FCF Ratio-4.11
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue30.95
Enterprise Value/Gross Profit83.40
Enterprise Value/Ebitda-2.31
Forecast
1Y Price Target
$38.25Price Target Upside1400.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$47.06M
Bulls Say, Bears Say
Bulls Say
KETAFREE Regulatory & Manufacturing ProgressA preliminary FDA bioequivalence finding plus a validated blow‑fill‑seal (BFS) process capable of ~1M units/week materially improves launch readiness. Durable manufacturing scale and a favorable regulatory posture reduce supply constraints versus compounded products and support a credible commercial rollout.
NRX-100 NDA Supported By Large RWE SetAn NDA strategy integrating substantial real‑world evidence (>65k patients) with clinical data can shorten development needs and strengthen regulatory arguments. FDA engagement on combined review and Fast Track status are structural advantages that increase the long‑term probability and speed of approval if the RWE SAP is agreed.
Debt Elimination And Post‑quarter Capital RaiseBecoming debt‑free and completing a post‑quarter ATM raise materially lowers near‑term solvency pressure. The improved capital structure and incremental cash provide runway to advance regulatory filings and initial commercialization efforts, reducing immediate refinancing urgency through key 2026 milestones.
Bears Say
Sustained Negative Cash FlowSubstantial TTM cash burn (~$14.9M) indicates operations are not self‑funding and will require repeated external capital or partner financing. Persisting negative free cash flow constrains strategic flexibility, increases dilution risk, and can slow program timelines if additional funding is delayed.
Negative Shareholders' Equity And Small Asset BaseA materially negative equity position reflects accumulated deficits and weak balance‑sheet reserves. Limited assets reduce borrowing flexibility and collateral options, raising the cost and difficulty of obtaining debt or strategic financings and heightening vulnerability to cash shocks during pivotal regulatory reviews.
Commercial Channel And Funding Execution RiskNRX must build dual commercial routes and displace compounded ketamine in clinics, a time‑consuming operational challenge. Key programs also depend on anticipated nondilutive grants; delays or failures in funding or channel adoption would slow revenue ramp and force additional financing or strategic tradeoffs.
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.62 and its highest was $4.58 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $160.86M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Aug 17, 2026 which is in 78 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on May 18, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of $0.209 by -$0.249.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.07.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 36,228,992 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, missing expectations of $0.209. Following the earnings report the stock price went down -5.03%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.25 (1400.00% Upside)
$38.25 (1400.00% Upside)
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.80%
12-Months-Change
Fundamentals
Return on Equity
107.73%
Trailing 12-Months
Asset Growth
56.82%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRXP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial forward progress across multiple fronts: near-term regulatory and manufacturing milestones for KETAFREE, an NRX-100 NDA supported by >65,000-patient RWE, FDA clearance to proceed with a sizable NRX-101 TMS augmentation trial (MIND1), expansion of HOPE clinics, and acquisition of Geneuro assets to broaden the pipeline. Financially, reported net loss improved materially (a 74% reduction year-over-year) and the company raised ~$7.0M post-quarter, while becoming debt-free. Counterbalancing these positives are near-term operational cash sensitivity, increased operating losses driven by higher R&D and G&A spend, ongoing regulatory timing risk, the need to build commercial channels (particularly to displace compounding pharmacy supply to clinics), and dependence on anticipated nondilutive funding for certain programs. Overall, the balance of concrete regulatory/operational advances and capital actions alongside manageable but material execution and timing risks supports a constructive outlook.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$38.25
▲(1400.00% Upside)
Technical Analysis
CervoMed
―
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
10.42%
Insiders
3.73% Mutual Funds
10.05% Other Institutional Investors
70.99% Public Companies and Individual Investors